The effect of HPV vaccination on the rate of high-grade cytology in 25-year-old women attending cervical screening in Ireland

Author:

Rourke Micheal,Fitzpatrick PatriciaORCID,Popoola Olalekan,Boms Rewhandamzi,Mooney Therese,Heavey Laura,Mohan Caroline Mason,Martin Cara M.,Jessop Lucy,Russell Noirin E.

Abstract

Abstract Introduction Women vaccinated through the initial catch-up HPV vaccination programme (2011/12 to 2013/14) first became eligible for cervical screening in 2019 at age 25. This study aims to examine the changes in detection of HG cytology outcomes in 25-year-olds screened from 2010 to 2022 compared to population data on HPV vaccination in this group. Methods This was an ecological-type study. Cytology results from the CervicalCheck database from 2010 to 2022 (High Grade, Low Grade, and No Abnormality Detected) were plotted against data from the National Immunisation Office on the uptake of HPV vaccinations in females from 2010 to 2022. Results Vaccination rates in the catch-up programme were lower (44–70%) than for routine HPV immunisation at age 12/13 in 2010/11 (81%). The rate of high-grade cytology in 25-year-olds in 2015–2018 was 3.7% of all cytology tests taken in this age group. For the corresponding period from 2019 to 2022 (when vaccinated women were attending screening), the average percentage of HG cytology in 25-year-olds was 1.5%, representing a significant reduction in HG cytology proportions (p < 0.001). Conclusion This study provides early evidence of the potential impact of HPV vaccination on cervical disease in the Republic of Ireland. Despite lower vaccination uptake in the initial catch-up group, we are seeing early signs of the positive protective effect of HPV vaccination in women at the time of their first cervical screening test. Plans to incorporate individual-level HPV vaccination status for women on the cervical screening register will allow more detailed assessment of the impact of HPV vaccination.

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Reference14 articles.

1. Global Health Objectives (2018) Special call for action: CERVICAL CANCER “An NCD We Can Overcome”. Geneva, Switzerland. Available at: https://www.who.int/director-general/speeches/detail/cervical-cancer-an-ncd-we-can-overcome

2. World Health Organisation (2020) Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva, Switzerland

3. Szarewski A, Poppe WAJ, Skinner SR et al (2012) Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 131(1):106–116

4. Health Protection Surveillance Centre (2013) HPV vaccine uptake in Ireland: 2011/2012. Dublin. Available at: https://www.hpsc.ie/az/vaccinepreventable/vaccination/immunisationuptakestatistics/hpvtdapmencmenacwyuptakestatistics/hpvimmunisationuptakereports2011-2018/File,14255,en.pdf

5. Corcoran B, Clarke A, Barrett T (2018) Rapid response to HPV vaccination crisis in Ireland. Lancet 391(10135):2103

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3